257 related articles for article (PubMed ID: 11544341)
1. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection.
Ferrari-Lacraz S; Zheng XX; Kim YS; Li Y; Maslinski W; Li XC; Strom TB
J Immunol; 2001 Sep; 167(6):3478-85. PubMed ID: 11544341
[TBL] [Abstract][Full Text] [Related]
2. CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein.
Ferrari-Lacraz S; Zheng XX; Fueyo AS; Maslinski W; Moll T; Strom TB
Transplantation; 2006 Dec; 82(11):1510-7. PubMed ID: 17164724
[TBL] [Abstract][Full Text] [Related]
3. Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade.
Ferrari-Lacraz S; Zheng XX; Kim YS; Maslinski W; Strom TB
Transplant Proc; 2002 May; 34(3):745-7. PubMed ID: 12034169
[No Abstract] [Full Text] [Related]
4. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance.
Steurer W; Nickerson PW; Steele AW; Steiger J; Zheng XX; Strom TB
J Immunol; 1995 Aug; 155(3):1165-74. PubMed ID: 7543517
[TBL] [Abstract][Full Text] [Related]
5. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts.
Jones TR; Ha J; Williams MA; Adams AB; Durham MM; Rees PA; Cowan SR; Pearson TC; Larsen CP
J Immunol; 2002 Feb; 168(3):1123-30. PubMed ID: 11801646
[TBL] [Abstract][Full Text] [Related]
6. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment.
Tran HM; Nickerson PW; Restifo AC; Ivis-Woodward MA; Patel A; Allen RD; Strom TB; O'Connell PJ
J Immunol; 1997 Sep; 159(5):2232-9. PubMed ID: 9278311
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic islet xenograft tolerance after short-term costimulation blockade is associated with increased CD4+ T cell apoptosis but not immune deviation.
Lehnert AM; Yi S; Burgess JS; O'Connell PJ
Transplantation; 2000 Mar; 69(6):1176-85. PubMed ID: 10762224
[TBL] [Abstract][Full Text] [Related]
8. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
[TBL] [Abstract][Full Text] [Related]
9. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
10. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
[TBL] [Abstract][Full Text] [Related]
11. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment.
Li Y; Zheng XX; Li XC; Zand MS; Strom TB
Transplantation; 1998 Nov; 66(10):1387-8. PubMed ID: 9846527
[TBL] [Abstract][Full Text] [Related]
12. An antagonist mutant IL-15/Fc promotes transplant tolerance.
Zheng XX; Gao W; Donskoy E; Neuberg M; Ruediger M; Strom TB; Moll T
Transplantation; 2006 Jan; 81(1):109-16. PubMed ID: 16421485
[TBL] [Abstract][Full Text] [Related]
13. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
14. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.
Coley SM; Ford ML; Hanna SC; Wagener ME; Kirk AD; Larsen CP
J Immunol; 2009 Jan; 182(1):225-33. PubMed ID: 19109153
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
17. Protection of corneal allografts by CTLA4-Ig.
Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
[TBL] [Abstract][Full Text] [Related]
18. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.
Sho M; Sandner SE; Najafian N; Salama AD; Dong V; Yamada A; Kishimoto K; Harada H; Schmitt I; Sayegh MH
Ann Surg; 2002 Nov; 236(5):667-75. PubMed ID: 12409674
[TBL] [Abstract][Full Text] [Related]
19. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.
Kim KS; Denton MD; Chandraker A; Knoflach A; Milord R; Waaga AM; Turka LA; Russell ME; Peach R; Sayegh MH
Am J Pathol; 2001 Mar; 158(3):977-86. PubMed ID: 11238045
[TBL] [Abstract][Full Text] [Related]
20. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival.
Smith XG; Bolton EM; Ruchatz H; Wei X; Liew FY; Bradley JA
J Immunol; 2000 Sep; 165(6):3444-50. PubMed ID: 10975865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
